公开(公告)号：US12054474B2

公开(公告)日：2024-08-06

申请号：US17962781

申请日：2022-10-10

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Colm Carroll ,  Anne Goldby ,  Martin Teall

IPC: A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  C07D211/96 ,  C07D401/12 ,  C07D401/14

CPC classification number: C07D401/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  C07D211/96 ,  C07D401/14

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof.




in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.

公开(公告)号：US20240059677A1

公开(公告)日：2024-02-22

申请号：US18025315

申请日：2021-09-10

Applicant: Cerevance, Inc. ,  TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Roland Werner Burli ,  Martin Teall ,  Nicola Brice

IPC: C07D403/12 ,  C07D401/12 ,  A61K45/06

CPC classification number: C07D403/12 ,  C07D401/12 ,  A61K45/06 ,  C07B2200/05 ,  C07B2200/07

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof wherein in, R1, R2, R3, L and X are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy particularly for use in treating disorders associated with nicotinic acetylcholine receptor α6 (nAChRα6) activity.

公开(公告)号：US11512066B2

公开(公告)日：2022-11-29

申请号：US16707079

申请日：2019-12-09

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Colm Carroll ,  Anne Goldby ,  Martin Teall

IPC: C07D401/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  C07D211/96 ,  C07D401/14

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.

公开(公告)号：US20170166553A1

公开(公告)日：2017-06-15

申请号：US15039650

申请日：2014-11-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Anne Goldby ,  Kerry Jenkins ,  Martin Teall

IPC: C07D401/14 ,  C07D401/04

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R3, R4 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

公开(公告)号：US10335402B2

公开(公告)日：2019-07-02

申请号：US15525417

申请日：2015-11-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Philip Mitchell ,  Martin Teall

IPC: A61K31/454 ,  C07D401/12

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, n, W, X, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification for use in treating irritable bowel syndrome or inflammatory bowel disease.

公开(公告)号：US20190084962A1

公开(公告)日：2019-03-21

申请号：US16194762

申请日：2018-11-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Colm Carroll ,  Anne Goldby ,  Martin Teall

IPC: C07D401/12 ,  C07D211/96 ,  A61K45/06 ,  A61K31/454 ,  C07D401/14 ,  A61K31/4545

CPC classification number: C07D401/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  C07D211/96 ,  C07D401/14

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.

公开(公告)号：US20150111922A1

公开(公告)日：2015-04-23

申请号：US14402751

申请日：2013-05-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Colm Carroll ,  Anne Goldby ,  Martin Teall

IPC: C07D401/14 ,  C07D401/12

CPC classification number: C07D401/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  C07D211/96 ,  C07D401/14

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof: (I) in which m, n, W, X, Y, Z, R1, R2, R3 and R4 are as defined in the specification, for use in the treatment or prevention of a diseases o conition mediated by a prokineticin, such as psychiatric and neurological conditions.

Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐：（I）其中m，n，w，X，Y，Z，R 1，R 2，R 3和R 4如本说明书中所定义， 治疗或预防由促运动素介导的疾病，如精神病学和神经病学疾病。

公开(公告)号：US20130324576A1

公开(公告)日：2013-12-05

申请号：US13904198

申请日：2013-05-29

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Colm Carroll ,  Anne Goldby ,  Martin Teall

IPC: C07D401/14 ,  C07D401/12 ,  A61K31/4545 ,  C07D211/96 ,  A61K45/06 ,  A61K31/454

CPC classification number: C07D401/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  C07D211/96 ,  C07D401/14

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R, R1, R2, R3 and R4 are as defined in the specification, for use in therapy.

Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐，其中m，n，w，X，Y，Z，R，R 1，R 2，R 3和R 4如本说明书中所定义，用于治疗。

公开(公告)号：US10562882B2

公开(公告)日：2020-02-18

申请号：US15039650

申请日：2014-11-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Anne Goldby ,  Kerry Jenkins ,  Martin Teall

IPC: C07D401/14 ,  C07D401/04

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R3, R4 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

公开(公告)号：US10160745B2

公开(公告)日：2018-12-25

申请号：US15702100

申请日：2017-09-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Sarah Bousba ,  Anne Goldby ,  Kerry Jenkins ,  Natasha Kinsella ,  Martin Teall

IPC: A61K31/454 ,  A61K31/4545 ,  C07D401/06 ,  C07D403/06 ,  A61K31/501 ,  A61K31/55 ,  C07D401/14

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R1, R2, R3 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions N containing them and their use in therapy.